140 related articles for article (PubMed ID: 33860387)
21. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
[TBL] [Abstract][Full Text] [Related]
22. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI
J Clin Oncol; 2016 Apr; 34(10):1065-71. PubMed ID: 26598746
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
24. The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
Crolley VE; Marashi H; Rawther S; Sirohi B; Parton M; Graham J; Vinayan A; Sutherland S; Rigg A; Wadhawan A; Harper-Wynne C; Spurrell E; Bond H; Raja F; King J
Breast Cancer Res Treat; 2020 Apr; 180(3):809-817. PubMed ID: 32170635
[TBL] [Abstract][Full Text] [Related]
25. Results of PONDx, a prospective multicenter study of the Oncotype DX
Curtit E; Vannetzel JM; Darmon JC; Roche S; Bourgeois H; Dewas S; Catala S; Mereb E; Fanget CF; Genet D; Forest AM; Bernier C; Pivot X
Breast; 2019 Apr; 44():39-45. PubMed ID: 30634106
[TBL] [Abstract][Full Text] [Related]
26. Oncotype DX and Prosigna in breast cancer patients: A comparison study.
Abdelhakam DA; Hanna H; Nassar A
Cancer Treat Res Commun; 2021; 26():100306. PubMed ID: 33444922
[TBL] [Abstract][Full Text] [Related]
27. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Martin M; Brase JC; Calvo L; Krappmann K; Ruiz-Borrego M; Fisch K; Ruiz A; Weber KE; Munarriz B; Petry C; Rodriguez CA; Kronenwett R; Crespo C; Alba E; Carrasco E; Casas M; Caballero R; Rodriguez-Lescure A
Breast Cancer Res; 2014 Apr; 16(2):R38. PubMed ID: 24725534
[TBL] [Abstract][Full Text] [Related]
28. Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.
Prat A; Galván P; Jimenez B; Buckingham W; Jeiranian HA; Schaper C; Vidal M; Álvarez M; Díaz S; Ellis C; Nuciforo P; Ferree S; Ribelles N; Adamo B; Ramón Y Cajal S; Peg V; Alba E
Clin Cancer Res; 2016 Feb; 22(3):560-6. PubMed ID: 26152740
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
[TBL] [Abstract][Full Text] [Related]
30. Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
Tesch ME; Speers C; Diocee RM; Gondara L; Peacock SJ; Nichol A; Lohrisch CA
Cancer; 2022 Feb; 128(4):665-674. PubMed ID: 34855202
[TBL] [Abstract][Full Text] [Related]
31. Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?
Markopoulos C; van de Velde C; Zarca D; Ozmen V; Masetti R
Eur J Surg Oncol; 2017 May; 43(5):909-920. PubMed ID: 27639633
[TBL] [Abstract][Full Text] [Related]
32. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
Fernandez-Martinez A; Pascual T; Perrone G; Morales S; de la Haba J; González-Rivera M; Galván P; Zalfa F; Amato M; Gonzalez L; Prats M; Rojo F; Manso L; Paré L; Alonso I; Albanell J; Vivancos A; González A; Matito J; González S; Fernandez P; Adamo B; Muñoz M; Viladot M; Font C; Aya F; Vidal M; Caballero R; Carrasco E; Altomare V; Tonini G; Prat A; Martin M
Oncotarget; 2017 Mar; 8(13):21930-21937. PubMed ID: 28423537
[TBL] [Abstract][Full Text] [Related]
33. Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study.
Dalenc F; Penault-Llorca F; Cohen M; Houvenaeghel G; Piat JM; Liegeois P; Puyuelo L; Suchaud JP; Zouai M; Lacroix-Triki M; Radosevic-Robin N; Benkanoun C; Attar-Rabia H; Chauvet MP; Gligorov J; Belkacemi Y
Clin Breast Cancer; 2017 Apr; 17(2):107-116. PubMed ID: 27856201
[TBL] [Abstract][Full Text] [Related]
34. Real-world economic value of a 21-gene assay in early-stage breast cancer.
Waintraub SE; McNamara D; Graham DMA; Pecora AL; Min J; Wu T; Noh HG; Connors J; Pe Benito R; Choi K; Schultz E; Goldberg SL
Am J Manag Care; 2017 Dec; 23(12):e416-e420. PubMed ID: 29261249
[TBL] [Abstract][Full Text] [Related]
35. Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
Jacobs VR; Kates RE; Kantelhardt E; Vetter M; Wuerstlein R; Fischer T; Schmitt M; Jaenicke F; Untch M; Thomssen C; Harbeck N
Breast Cancer Res Treat; 2013 Apr; 138(3):839-50. PubMed ID: 23568480
[TBL] [Abstract][Full Text] [Related]
36. Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer.
Albanell J; Svedman C; Gligorov J; Holt SD; Bertelli G; Blohmer JU; Rouzier R; Lluch A; Eiermann W
Eur J Cancer; 2016 Oct; 66():104-13. PubMed ID: 27544930
[TBL] [Abstract][Full Text] [Related]
37. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
38. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
de Nonneville A; Gonçalves A; Zemmour C; Classe JM; Cohen M; Lambaudie E; Reyal F; Scherer C; Muracciole X; Colombo PE; Giard S; Rouzier R; Villet R; Chopin N; Darai E; Garbay JR; Gimbergues P; Sabiani L; Coutant C; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
Breast Cancer Res Treat; 2017 Apr; 162(2):307-316. PubMed ID: 28155054
[TBL] [Abstract][Full Text] [Related]
39. The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis.
Weiser R; Haque W; Polychronopoulou E; Hatch SS; Kuo YF; Gradishar WJ; Klimberg VS
Breast Cancer Res Treat; 2021 Feb; 185(3):667-676. PubMed ID: 33070279
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.
Berdunov V; Millen S; Paramore A; Hall P; Perren T; Brown R; Griffin J; Reynia S; Fryer N; Longworth L
J Med Econ; 2022; 25(1):591-604. PubMed ID: 35416089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]